drugset / Trial / NCT04539262
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019 (COVID-19).
Timeline
- Start
- 2020-09-14
- Primary completion
- 2021-02-26
- Completion
- 2021-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remdesivir | Small molecule | 31 mg | Inhaled |
| Subject | Remdesivir | Small molecule | 39 mg | Inhaled |
| Subject | Remdesivir | Small molecule | 62 mg | Inhaled |